Jevtana Disease Interactions
There are 7 disease interactions with Jevtana (cabazitaxel).
- Infections
- Hepatic impairment
- Myelosuppression
- Renal failure
- GI complications
- Hemodialysis
- Pulmonary impairment
Antineoplastics (applies to Jevtana) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
References
- "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
- "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
- "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
- "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
- "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
- "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
- "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
- "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
- "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
- "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
- "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
- "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
- "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
- "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
- "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
- "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
- "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
- "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
- "Product Information. Halaven (eribulin)." Eisai Inc (2010):
- "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
Cabazitaxel (applies to Jevtana) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Cabazitaxel is extensively metabolized in the liver and is contraindicated in patients with severe hepatic impairment. Caution and close monitoring is recommended when prescribing this agent to patients with mild or moderate hepatic impairment and dosage reduction should be considered for these patients.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Cabazitaxel (applies to Jevtana) myelosuppression
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever, Anemia
The use of cabazitaxel is contraindicated in patients with neutrophils count less than or equal to 1,500/mm3. The use of cabazitaxel may cause bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia. Prophylaxis therapy should be considered in patients with high-risk clinical features (age >65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia. Cautions should be exercised in patients using cabazitaxel with hemoglobin counts of less than 10 g/dL. It is recommended to monitor complete blood counts on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Cabazitaxel (applies to Jevtana) renal failure
Major Potential Hazard, Moderate plausibility. Applicable conditions: Sepsis, Dehydration, Urinary Tract Obstruction
Renal failure, sometimes with fatal outcomes has been documented with the use of cabazitaxel in clinical studies and most cases have occurred in association with sepsis, dehydration, or obstructive uropathy. Care and appropriate measures should be taken when prescribing this agent to these patients.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Cabazitaxel (applies to Jevtana) GI complications
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Gastrointestinal Hemorrhage, Gastrointestinal Obstruction, Peptic Ulcer
Gastrointestinal hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with cabazitaxel. Risk may be increased with neutropenia, age, steroid use, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy, adhesions, ulceration and GI bleeding. It is recommended to monitor closely for early manifestations of serious gastrointestinal toxicity and to delay or discontinue treatment if necessary, in particular if patients experience Grade >=3 diarrhea.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Cabazitaxel (applies to Jevtana) hemodialysis
Moderate Potential Hazard, Moderate plausibility.
Cabazitaxel is minimally excreted via the kidney and its use does not require dosage adjustment in patients with renal impairment not requiring hemodialysis. Patients presenting with end-stage renal disease should be monitored carefully during treatment with cabazitaxel.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Cabazitaxel (applies to Jevtana) pulmonary impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Interstitial Pneumonitis
Interstitial lung disease/pneumonitis and acute respiratory distress syndrome have been reported with the use of cabazitaxel. Patients with underlying lung disease may be at higher risk for these events. Acute respiratory distress syndrome may occur in the setting of infection. Treatment interruption or discontinuation may be necessary if new or worsening of pulmonary symptoms develop. Close monitoring is recommended. The benefits of resuming therapy should be carefully evaluated.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Jevtana drug interactions
There are 432 drug interactions with Jevtana (cabazitaxel).
More about Jevtana (cabazitaxel)
- Jevtana consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: mitotic inhibitors
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.